Home › Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia clinical trials recruiting in the U.S.
122 studies for Chronic Lymphocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA32 studies
- Columbus, OH29 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA21 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Chicago, IL14 studies
- Milwaukee, WI14 studies
- Cincinnati, OH14 studies
- Nashville, TN13 studies
- Atlanta, GA11 studies
- Jacksonville, FL11 studies
- Philadelphia, PA11 studies
- Portland, OR10 studies
- Kansas City, MO10 studies
- Pittsburgh, PA10 studies
- San Diego, CA10 studies
- Salt Lake City, UT10 studies
- Dallas, TX10 studies
- Charlotte, NC9 studies
- Miami, FL9 studies
- Queens, NY8 studies
- Los Angeles, CA8 studies
- Omaha, NE8 studies
- Minneapolis, MN8 studies
- Winston-Salem, NC8 studies
- Tampa, FL8 studies
- St. Louis, MO8 studies
- Des Moines, IA8 studies
- Denver, CO8 studies
- Fort Wayne, IN7 studies
- Billings, MT7 studies
- Cleveland, OH7 studies
- Eugene, OR7 studies
- Aurora, CO7 studies
- Clifton, NJ7 studies
- Mountain View, CA7 studies
By state
- Alabama7 studies
- Arizona14 studies
- Arkansas4 studies
- California34 studies
- Colorado16 studies
- Connecticut5 studies
- Delaware4 studies
- District of Columbia4 studies
- Florida34 studies
- Georgia16 studies
- Idaho4 studies
- Illinois17 studies
- Indiana12 studies
- Iowa10 studies
- Kansas6 studies
- Kentucky7 studies
- Louisiana6 studies
- Maine6 studies
- Maryland23 studies
- Massachusetts34 studies
- Michigan12 studies
- Minnesota29 studies
- Mississippi5 studies
- Missouri13 studies
- Montana7 studies
- Nebraska8 studies
- Nevada6 studies
- New Hampshire3 studies
- New Jersey13 studies
- New Mexico3 studies
- New York26 studies
- North Carolina34 studies
- Ohio44 studies
- Oklahoma4 studies
- Oregon17 studies
- Pennsylvania22 studies
- Rhode Island5 studies
- South Carolina5 studies
- South Dakota4 studies
- Tennessee17 studies
- Texas38 studies
- Utah10 studies
- Virginia11 studies
- Washington27 studies
- Wisconsin19 studies
Recently updated studies
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06846671Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
RecruitingPhase 2
Ages 75 and older · All sexes · Updated Sep 28, 2026 · NCT07685717A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06697184A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 24, 2026 · NCT03986034Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07194980Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07061951Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04169737Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05091424Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.